Opexa is funded through to the H216 readout of its Phase IIb Abili-T study of Tcelna in secondary progressive multiple sclerosis (SPMS). SPMS affects 30-45% of the approximately two million worldwide MS patients and an approved treatment could generate more than $5bn in US sales.
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Personalised MS immunotherapy
- Published:
20 Aug 2015 - Author:
- Pages:
Opexa is funded through to the H216 readout of its Phase IIb Abili-T study of Tcelna in secondary progressive multiple sclerosis (SPMS). SPMS affects 30-45% of the approximately two million worldwide MS patients and an approved treatment could generate more than $5bn in US sales.